Regenerative Patch Technologies
CA - Menlo ParkMedical Devices
Focus: Regenerative Patch Technologies is an early-stage medical device company focused on cell-based implant technology for retinal diseases, specifically dry age-related macular degeneration. Founded in 2023 and based in Menlo Park, CA, the company is pre-revenue with a highly focused therapeutic pipeline.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Open Jobs
0
About Regenerative Patch Technologies
AI assessmentNot HiringNo open roles listed right now. Follow Regenerative Patch Technologies to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
CPCB-RPE1
Dry Macular DegenerationClinical Trials (1)
NCT02590692Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD
Phase 1/2Help build intelligence for Regenerative Patch Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.